CADL Stock Soars as Phase III Prostate Cancer Study Meets Primary Goal

Published on 12 Dec 2024 on Zacks · via Yahoo Finance

Candel stock rallies 68% on meeting the primary goal in a phase III study of CAN-2409 combo therapy...

Read the rest of the article

Start tracking your investments with Statfolio

Candel Therapeutics, Inc. (NASDAQ:CADL) insiders who acquired shares over the previous 12 months,...

Simply Wall St. · via Yahoo Finance 18 Jan 2025

Candel Therapeutics Inc (NASDAQ:CADL) announced on Monday the completion of a public offering tha...

Proactive Investors 17 Dec 2024

Shares of Candel Therapeutics, Inc. (NASDAQ:CADL) saw a 30% decrease in premarket trading today...

Investing.com 13 Dec 2024

Candel Therapeutics Inc (NASDAQ:CADL) has announced an $80 million underwritten public offering o...

Proactive Investors 13 Dec 2024

Candel Therapeutics, Inc. CADL shares are moving lower on Friday after the company priced its $80...

Benzinga 13 Dec 2024

Candel stock rallies 68% on meeting the primary goal in a phase III study of CAN-2409 combo thera...

Zacks · via Yahoo Finance 12 Dec 2024

U.S. stocks mixed at close of trade; Dow Jones Industrial Average down 0.22%

Investing.com 12 Dec 2024

On Wednesday, Candel Therapeutics, Inc. (NASDAQ:CADL) announced results from a phase 3 trial of...

Benzinga · via Yahoo Finance 11 Dec 2024

By Karen Roman Candel Therapeutics, Inc. (Nasdaq: CADL) said Phase 3 of its prostate cancer...

Exec Edge · via Yahoo Finance 11 Dec 2024

U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 300...

Benzinga 11 Dec 2024